ArticleFrontiers in immunology2026
Diagnostic value and immune microenvironment regulatory network of metabolic reprogramming in chronic rhinosinusitis with nasal polyps identified by multidimensional transcriptome integration and machine learning.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Rhinosinusitis with Nasal polyps (CRSwNP) are characterized by chronic inflammation and occur in 1-4% of the population worldwide. Patients often have comorbid asthma, and standard treatments among them are hindered by significant recurrence and lack of durability. Currently, knowledge of the molecular circuitry and immune microenvironmental interplay that utilizes metabolic reprogramming within CRSwNP is incomplete. Methods: Utilizing CRSwNP datasets from the GEO database, we performed bioinformatics analysis to identify differentially expressed genes (DEGs) implicated in metabolic reprogramming. Key regulatory genes were subsequently selected by weighted gene co-expression network analysis (WGCNA) and machine learning algorithms; their relationship with the immune microenvironment was then evaluated. To further investigate the underlying pathogenic mechanisms, we performed single-cell RNA sequencing (scRNA-seq) to map cellular expression patterns and applied Mendelian randomization (MR) analysis to assess potential causal relationships. Key molecules were subsequently experimentally validated by quantitative real-time PCR (qRT-PCR). Results: We identified 21 DEGs associated with metabolic reprogramming that are relevant to CRSwNP. This subset was then analyzed using machine learning to identify 8 hub genes - ERBB4, FBP1, HMGCS2, LYZ, NDRG2, PIP, PYCR1, and SLC43A1. A prediction model built using these biomarkers yielded high diagnostic performance (AUC = 0.979). Single-cell resolution analysis revealed that distinct expression patterns were exhibited by these genes across subsets of immune cells. MR analysis determined that lower expression of FBP1, LYZ and NDRG2 could be risk factors for CRSwNP. Subsequent qRT-PCR in independent samples validated the downregulation of these genes in CRSwNP tissues. Conclusions: We systematically identify and validate a set of metabolic reprogramming-related genes with diagnostic value in CRSwNP. Collectively, these findings not only heighten the current mechanistic understanding of CRSwNP pathogenesis but also offer a novel platform to devise diagnostic and therapeutic avenues focusing on metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.